HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Virology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/VIRO.1993.1027PMID 7685964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HIV Inhibitors Targeted at the Reverse Transcriptase

  1992cited by this paper
• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

  1992cited by this paper
• 3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides.

  1992cited by this paper
• In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.

  1992cited by this paper
• Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.

  1992cited by this paper
• 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.

  1992cited by this paper
• TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.

  1992cited by this paper
• Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.

  1991cited by this paper
• Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

  1991cited by this paper
• Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors.

  1991cited by this paper
• Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase.

  1991cited by this paper
• Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

  1991cited by this paper
• A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site.

  1991cited by this paper
• Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.

  1991cited by this paper
• Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

  1991cited by this paper
• HIV-1 Reverse Transcriptase: Structure Predictions for the Polymerase Domain

  1990cited by this paper
• Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

  1990cited by this paper
• Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

  1990cited by this paper
• Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

  1989cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper
• Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.

  1989cited by this paper
• Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

  1984cited by this paper
• Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

  1983cited by this paper

• Aloperine-Type Alkaloids from Sophora alopecuroides as Promising Reverse Transcriptase Inhibitors for Human and Feline Immunodeficiency Viruses: Structure-Based Evaluation

  2025cites this paper
• Structural biology of HIV-1 reverse transcriptase allosteric inhibitors for drug design

  2025cites this paper
• Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.

  2022cites this paper
• Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs

  2020cites this paper
• Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N, E138K Mutants, and Pharmacokinetic Profiles.

  2020cites this paper
• Graphene Quantum Dots Based Systems As HIV Inhibitors.

  2018cites this paper
• Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.

  2017cites this paper
• Searching for novel N1-substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors.

  2017cites this paper
• 1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.

  2016cites this paper
• Synthesis and anti-HIV activity of carboxylated and drug-conjugated multi-walled carbon nanotubes

  2015cites this paper
• Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.

  2014cites this paper
• Selective inhibition of human inmunodeficiency virus type 1 ( HIV-1 ) by nucleoside analogues with an unusual tricyclic structure

  2014cites this paper
• Selective inhibition of Human Immunodeficiency Virus type 1 (HIV-1) by a novel family of tricyclic nucleosides.

  2011cites this paper
• Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.

  2011cites this paper
• Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

  2010cites this paper
• Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance

  2010cites this paper
• Clinical management of HIV-1 resistance.

  2010cites this paper
• Studies of Anti‐HIV Transcription Inhibitor Quinolones: Identification of Potent N1‐Vinyl Derivatives

  2010cites this paper
• Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.

  2009cites this paper
• Estratègies de simplificació del tractament antiretroviral en diferents estadiatges de la infecció pel VIH-1

  2009cites this paper
• A Multidisciplinary Approach for the Identification of Novel HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors: S‐DABOCs and DAVPs

  2008cites this paper
• Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.

  2008cites this paper
• Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.

  2008cites this paper
• Novel N-3 Substituted TSAO-T Derivatives: Synthesis and Anti-HIV-Evaluation

  2008influential citation
• Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents.

  2007cites this paper
• Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate.

  2007cites this paper
• Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.

  2007cites this paper
• Antiviral resistance : mechanisms , clinical significance , and future implications

  2005cites this paper
• Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position.

  2005cites this paper
• First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.

  2005cites this paper
• Nucleoside Analogues Exerting Antiviral Activity Through a Non‐nucleoside Mechanism

  2004cites this paper
• Structure modifications of 6-aminoquinolones with potent anti-HIV activity.

  2004cites this paper
• Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future

  2004cites this paper
• 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.

  2004cites this paper
• TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase.

  2004cites this paper
• Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents.

  2004cites this paper
• Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

  2004cites this paper
• N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action.

  2003cites this paper
• Drug Discovery Strategies and Methods

  2003cites this paper
• Inhibition of Human Immunodeficiency Virus by a New Class of Pyridine Oxide Derivatives

  2003cites this paper
• Viral ion channels: structure and function.

  2002cites this paper
• In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.

  2002cites this paper
• Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations

  2001cites this paper
• Exploitation of the Low Fidelity of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase and the Nucleotide Composition Bias in the HIV-1 Genome To Alter the Drug Resistance Development of HIV

  2001cites this paper
• Antiviral activity of 4-benzyl pyridinone derivatives as HIV-1 reverse transcriptase inhibitors

  2001cites this paper
• Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.

  2001cites this paper
• Synthesis, Biological Activity, Pharmacokinetic Properties and Molecular Modelling Studies of Novel 1H,3H-Oxazolo[3,4-a]Benzimidazoles: Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

  2001influential citation
• Highly Stereoselective Synthesis and Biological Properties of Nucleoside Analogues Bearing a Spiro Inserted Oxirane Ring

  2000cites this paper
• Presence of 2' ,5'-Bis-O-(tert-butyldimethylsilyl)-3-spiro-5"(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO)-Resistant Virus Strains in TSAO-Inexperienced HIV Patients

  2000cites this paper
• Pyrido [1,2a] Indole Derivatives Identified as Novel Nonnucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1

  1999cites this paper
• Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3'-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs.

  1999cites this paper
• HIV Resistance to Antagonists of Viral Reverse Transcriptase

  1999cites this paper
• Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.

  1999cites this paper
• 1,1,3-Trioxo-2H,4H-Thieno[3,4-e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity

  1998cites this paper
• An Approach towards the Synthesis of Potential Metal-Chelating TSAO-T Derivatives as Bidentate Inhibitors of Human Immunodeficiency virus Type 1 Reverse Transcriptase

  1998cites this paper
• Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase.

  1998cites this paper
• Non-nucleoside inhibitors of HIV-1 reverse transcriptase

  1998cites this paper
• Imidazo[1,5-b]Pyridazine-D4T Conjugates: Synthesis and Anti-Human Immunodeficiency Virus Evaluation

  1998cites this paper
• Anticonvulsant phenytoinergic pharmacophores and anti-HIV activity--preliminary evidence for the dual requirement of the 4-aminophthalimide platform and the N-(1-adamantyl) substitution for antiviral properties.

  1998cites this paper
• Regiospecific Synthesis and Anti-Human Immunodeficiency Virus Activity of Novel 5-Substituted N-Alkylcarbamoyl and N,N-Dialkyl Carbamoyl 1,2,3-Triazole-TSAO Analogues

  1998cites this paper
• Structure-based design of inhibitors of HIV-1 reverse transcriptase: a potential class of bidentate nonnucleoside inhibitors

  1998cites this paper
• A rapid and quantitative assay for inhibition of 3' cleavage activity of HIV-1 integrase.

  1997cites this paper
• Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2',6'-difluorophenyl)-l H,3H-thiazo­ lo(3,4-a)benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor

  1997cites this paper
• Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.

  1997cites this paper
• Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice.

  1997cites this paper
• The existence of human immunodeficiency virus resistance to nucleoside-analog drugs has not been shown.

  1997cites this paper
• SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus

  1997cites this paper
• Selected Nucleotide Sequence of the pol Gene of the Monocytotropic Strain HIV Type 1 BaL

  1997cites this paper
• Anti-HIV activity of N-1-adamantyl-4-aminophthalimide.

  1997cites this paper
• Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.

  1997cites this paper
• MOLECULAR BIOLOGY OF HUMAN IMMUNODEFICIENCY VIRUSES: HIV-l AND HIV-2

  1997cites this paper
• SRR-SB 3 , a Disulfide-Containing Macrolide That Inhibits a Late Stage of the Replicative Cycle of Human Immunodeficiency Virus

  1997cites this paper
• Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.

  1997cites this paper
• Clonal Selection of HIV Type 1 Variants Associated with Resistance to Foscarnet in Vitro: Confirmation by Molecular Evolutionary Analysis

  1997cites this paper
• Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants.

  1997cites this paper
• Specific inhibition of human immunodeficiency virus type 1 reverse transcriptase mediated by soulattrolide, a coumarin isolated from the latex of calophyllum teysmannii.

  1996cites this paper
• Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.

  1996cites this paper
• Development of nonnucleoside HIV reverse transcriptase inhibitors.

  1996cites this paper
• Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.

  1996cites this paper
• Structural mechanisms of HIV drug resistance.

  1996cites this paper
• Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.

  1996cites this paper
• Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus

  1996influential citation
• Antiviral resistance: mechanisms, clinical significance, and future implications.

  1996cites this paper
• Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.

  1996cites this paper
• Inhibitory effect of 4‐(2,6‐dichlorophenyl)‐1,2,5‐thiadiazol‐3‐yl‐N‐methyl, N‐ethylcarbamate on replication of human immunodeficiency virus type 1 and the mechanism of action

  1996cites this paper
• Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

  1996cites this paper
• Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle.

  1996cites this paper
• What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?

  1996cites this paper
• The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication

  1996cites this paper
• Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors.

  1996cites this paper
• Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.

  1996cites this paper
• Use of Viral Resistance Patterns to Antiretroviral Drugs in Optimising Selection of Drug Combinations and Sequences

  1996cites this paper
• Analysis of inhibition of retroviral reverse transcriptase.

  1996cites this paper
• Mutations in RT and Protease III -93 NOV 95 Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance

  1996cites this paper
• Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

  1996cites this paper
• HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.

  1996cites this paper
• Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity.

  1996cites this paper
• Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

  1996cites this paper
• The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors

  1996cites this paper
• A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1.

  1996cites this paper